Our current work on ADDIS 2 is part of the IMI GetReal project. The ADDIS 1 project was funded by TI Pharma's Escher project. Additional funding for the further development of the MCDA user interface was received from the IMI PROTECT project.

GetReal (IMI, 2013 - 2016) GetReal

Incorporating real-life clinical data into drug development

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in "real world" clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA agencies and other healthcare decision makers have to make decisions on authorisation and access under conditions of uncertainty. Currently, data packages which aim to minimise uncertainty on safety and efficacy may leave significant uncertainty in assessments of real world effectiveness of new medicines. This results in further research commitments required post-authorisation, and wide variability in access to medicines between countries.

The GetReal consortium aims to improve the efficiency of the medicine development process by better incorporating real-life clinical data into drug development and to enrich decision-making by regulatory authorities and HTA bodies. GetReal is a public-private partnership between key European stakeholders and leading research groups. These include the EMA, the Dutch reimbursement body CvZ that is a member of the EUnetHTA network in which the various reimbursement bodies throughout Europe are bundling their expertise on Health Technology Assessment, and the International Alliance of Patients' Organizations (IAPO) that covers patient organizations all over the world. GetReal creates impact by developing a set of tools, decision frameworks, methods and insights to include real clinical data in drug development.

The ADDIS 2 project is part of work package 4, promoting best practice in evidence synthesis and predictive modelling of relative effectiveness. Methodological issues to be addressed focus on the combination of data from the mix of randomised and observational studies that are typically available at the launch of a new medicine. We will develop and promote user-friendly software to support evidence synthesis and predictive modelling of pharmaceutical therapies.

Escher Project (TI Pharma, 2008 - 2013) Escher

Science-driven drug regulation

Our work on ADDIS 1.x was funded by the Dutch Top Institute Pharma, specifically through the Escher Project workpackage 3.2. The goal of the Escher project was to "engergize pharmaceutical R&D by identifying, evaluating and removing regulatory barriers to bring effacious and safe medicines to patients in an efficient and timely fashion."

In workpackage 3.2, we created evidence-based drug information repositories in which drug efficacy and safety questions can be answered in an efficient, transparent and accountable way. Comparisons within and across medicinal products can now be made in a more automated and, hence, more efficient way.

The following resources were funded by Escher WP 3.2:

  • Dr. Tommi Tervonen, post-doc researcher (2008-09 - 2010-08)
  • Gert van Valkenhoef, PhD student (2009-04 - 2012-12)
  • Software development (1-3 part-time developers, 2009-10 - 2013-06)

Through the commissioned project "industry requirements and a data standard for ADDIS"

  • Hans van Leeuwen
  • Prof. dr. Jozef Aerts

Through the commissioned project "decision support for benefit-risk assessment with imprecise preference information"

  • Dr. Gert van Valkenhoef, post-doc researcher (2013-01 - 2013-06)